Buy Vytorin through the unique service that maximize your savings

A controversial study showing that the blockbuster cholesterol-lowering drug Vytorin failed to slow the buildup of artery plaques more than a cheaper statin is certain to provoke questions among heart patients taking Vytorin or its sister drug Zetia. USA TODAY medical reporter Steve Sternberg asked Steven Nissen, the Cleveland Clinic’s chief of cardiology, and Roger Blumenthal of the Johns Hopkins Ciccarone Center for the Prevention of Heart Disease and the Americ…